Form 4: Apellis Pharmaceuticals Executive Exercises Stock Options
SEC Form 4 Filing
David O. Watson, General Counsel of Apellis Pharmaceuticals, exercised stock options and reported changes in beneficial ownership.
Summary
- On March 6, 2024, David O. Watson, General Counsel of Apellis Pharmaceuticals, exercised stock options to acquire 3,762 shares of common stock at a price of $13.85 per share.
- Following the transaction, Watson directly owns 107,152 shares of Apellis common stock.
- Watson also has indirect ownership of shares through a custodial account for his son (3,333 shares), The David O. Watson Irrevocable Trust of 2023 (80,705 shares), and The Watson Education Trust (6,667 shares).
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard SEC filing related to stock option exercise.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the increase in outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 02/08/2019 | Date stock option was granted. |
| 02/07/2029 | Expiration date of the stock option. |
| 03/06/2024 | Date of the transaction (exercise of stock options). |
| 03/08/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.